首页 > 最新文献

Future Virology最新文献

英文 中文
Efficiency rating of SG Diagnostics COVID-19 antigen rapid test kit. SG Diagnostics新冠病毒抗原快速检测试剂盒效率评价。
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2023-03-01 DOI: 10.2217/fvl-2021-0210
Francesco Chirico, Murat Yıldırım, Tomasz Dzieciatkowski, Marek Dabrowski, Marek Malysz, Marcin Madziala, Milosz Jaroslaw Jaguszewski, Karol Bielski, Gabriella Nucera, Krzysztof J Filipiak, Lukasz Szarpak

Aim: Rapid detection is crucial in complementing vaccination to reduce transmission of SARS-CoV-2. Materials & methods: Nasopharyngeal swabs (n = 213) and oropharyngeal swabs (n = 98) were tested. with the antigen rapid test kit. Results: Overall sensitivity (97.96%), specificity (100.00%) and coincidence rate (98.71%) were high, which translated into a positive predictive value of 100.00% and a negative predictive value of 96.64%. Conclusion: Antigen rapid tests have a great potential for screening in different settings to deliver results with high sensitivity and specificity.

目的:快速检测对于补充疫苗接种以减少SARS-CoV-2的传播至关重要。材料与方法:对鼻咽拭子(n = 213)和口咽拭子(n = 98)进行检测。用抗原快速检测试剂盒。结果:总灵敏度(97.96%)、特异度(100.00%)和符合率(98.71%)较高,阳性预测值为100.00%,阴性预测值为96.64%。结论:抗原快速检测在不同环境下的筛查具有很大的潜力,可提供高灵敏度和特异性的结果。
{"title":"Efficiency rating of SG Diagnostics COVID-19 antigen rapid test kit.","authors":"Francesco Chirico,&nbsp;Murat Yıldırım,&nbsp;Tomasz Dzieciatkowski,&nbsp;Marek Dabrowski,&nbsp;Marek Malysz,&nbsp;Marcin Madziala,&nbsp;Milosz Jaroslaw Jaguszewski,&nbsp;Karol Bielski,&nbsp;Gabriella Nucera,&nbsp;Krzysztof J Filipiak,&nbsp;Lukasz Szarpak","doi":"10.2217/fvl-2021-0210","DOIUrl":"https://doi.org/10.2217/fvl-2021-0210","url":null,"abstract":"<p><p><b>Aim:</b> Rapid detection is crucial in complementing vaccination to reduce transmission of SARS-CoV-2. <b>Materials & methods:</b> Nasopharyngeal swabs (n = 213) and oropharyngeal swabs (n = 98) were tested. with the antigen rapid test kit. <b>Results:</b> Overall sensitivity (97.96%), specificity (100.00%) and coincidence rate (98.71%) were high, which translated into a positive predictive value of 100.00% and a negative predictive value of 96.64%. <b>Conclusion:</b> Antigen rapid tests have a great potential for screening in different settings to deliver results with high sensitivity and specificity.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115194/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9445403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
In silico analysis of ACE2 from different animal species provides new insights into SARS-CoV-2 species spillover. 不同动物物种ACE2的计算机分析为SARS-CoV-2物种溢出提供了新的见解。
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2023-03-01 DOI: 10.2217/fvl-2022-0187
Felipe Pantoja Mesquita, Pedro Filho Noronha Souza, Dyane Rocha Aragão, Expedito Maia Diógenes, Emerson Lucena da Silva, Jackson Lima Amaral, Valder Nogueira Freire, Débora de Souza Collares Maia Castelo-Branco, Raquel Carvalho Montenegro

Aim: This study aimed to analyze the phylogenetic relationships between the ACE2 of humans and other animals and investigate the potential interaction between SARS-CoV-2 RBD and ACE2 of different species. Materials & methods: The phylogenetic construction and molecular interactions were assessed using computational models. Results & conclusion: Despite the evolutionary distance, 11 species had a perfect fit for the interaction between their ACE2 and SARS-CoV-2 RBD (Chinchilla lanigera, Neovison vison, Rhinolophus sinicus, Emballonura alecto, Saccopteryx bilineata, Numida meleagris). Among them, the avian N. meleagris was reported for the first time in this study as a probable SARS-CoV-2 host due to the strong molecular interactions. Therefore, predicting potential hosts for SARS-CoV-2 for understanding the epidemiological cycle and proposal of surveillance strategies.

目的:分析人与其他动物ACE2的系统发育关系,探讨不同物种SARS-CoV-2 RBD与ACE2的潜在相互作用。材料与方法:使用计算模型评估系统发育结构和分子相互作用。结果与结论:尽管进化距离较远,但11个物种(Chinchilla lanigera, Neovison vison, Rhinolophus sinicus, Emballonura alecto, Saccopteryx bilineata, Numida meleagris)的ACE2与SARS-CoV-2 RBD的相互作用完全吻合。其中,禽类N. meleagris因具有较强的分子相互作用,在本研究中首次被报道为可能的SARS-CoV-2宿主。因此,预测SARS-CoV-2的潜在宿主有助于了解流行病学周期并提出监测策略。
{"title":"<i>In silico</i> analysis of <i>ACE2</i> from different animal species provides new insights into SARS-CoV-2 species spillover.","authors":"Felipe Pantoja Mesquita,&nbsp;Pedro Filho Noronha Souza,&nbsp;Dyane Rocha Aragão,&nbsp;Expedito Maia Diógenes,&nbsp;Emerson Lucena da Silva,&nbsp;Jackson Lima Amaral,&nbsp;Valder Nogueira Freire,&nbsp;Débora de Souza Collares Maia Castelo-Branco,&nbsp;Raquel Carvalho Montenegro","doi":"10.2217/fvl-2022-0187","DOIUrl":"https://doi.org/10.2217/fvl-2022-0187","url":null,"abstract":"<p><p><b>Aim:</b> This study aimed to analyze the phylogenetic relationships between the ACE2 of humans and other animals and investigate the potential interaction between SARS-CoV-2 RBD and ACE2 of different species. <b>Materials & methods:</b> The phylogenetic construction and molecular interactions were assessed using computational models. <b>Results & conclusion:</b> Despite the evolutionary distance, 11 species had a perfect fit for the interaction between their ACE2 and SARS-CoV-2 RBD (<i>Chinchilla lanigera, Neovison vison</i>, <i>Rhinolophus sinicus, Emballonura alecto</i>, <i>Saccopteryx bilineata</i>, <i>Numida meleagris</i>). Among them, the avian <i>N. meleagris</i> was reported for the first time in this study as a probable SARS-CoV-2 host due to the strong molecular interactions. Therefore, predicting potential hosts for SARS-CoV-2 for understanding the epidemiological cycle and proposal of surveillance strategies.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10096339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9321831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Evidence-based policies in public health to address COVID-19 vaccine hesitancy. 基于证据的公共卫生政策解决COVID-19疫苗犹豫问题。
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2023-03-01 Epub Date: 2023-04-04 DOI: 10.2217/fvl-2022-0028
Francesco Chirico, Jaime A Teixeira da Silva

A fundamental basis for effective health-related policymaking of any democratic nation should be open and transparent communication between a government and its citizens, including scientists and healthcare professionals, to foster a climate of trust, especially during the ongoing COVID-19 mass vaccination campaign. Since misinformation is a leading cause of vaccine hesitancy, open data sharing through an evidence-based approach may render the communication of health strategies developed by policymakers with the public more effective, allowing misinformation and claims that are not backed by scientific evidence to be tackled. In this narrative review, we debate possible causes of COVID-19 vaccine hesitancy and links to the COVID-19 misinformation epidemic. We also put forward plausible solutions as recommended in the literature.

任何民主国家有效制定健康相关政策的基本基础都应该是政府与其公民(包括科学家和医疗保健专业人员)之间公开透明的沟通,以营造信任气氛,尤其是在正在进行的新冠肺炎大规模疫苗接种运动期间。由于错误信息是疫苗犹豫的主要原因,通过循证方法进行公开数据共享可能会使政策制定者制定的健康战略与公众的沟通更加有效,从而能够解决没有科学证据支持的错误信息和说法。在这篇叙述性综述中,我们讨论了新冠肺炎疫苗犹豫的可能原因以及与新冠肺炎错误信息流行的联系。我们还根据文献中的建议提出了合理的解决方案。
{"title":"Evidence-based policies in public health to address COVID-19 vaccine hesitancy.","authors":"Francesco Chirico,&nbsp;Jaime A Teixeira da Silva","doi":"10.2217/fvl-2022-0028","DOIUrl":"10.2217/fvl-2022-0028","url":null,"abstract":"<p><p>A fundamental basis for effective health-related policymaking of any democratic nation should be open and transparent communication between a government and its citizens, including scientists and healthcare professionals, to foster a climate of trust, especially during the ongoing COVID-19 mass vaccination campaign. Since misinformation is a leading cause of vaccine hesitancy, open data sharing through an evidence-based approach may render the communication of health strategies developed by policymakers with the public more effective, allowing misinformation and claims that are not backed by scientific evidence to be tackled. In this narrative review, we debate possible causes of COVID-19 vaccine hesitancy and links to the COVID-19 misinformation epidemic. We also put forward plausible solutions as recommended in the literature.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10093330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
The impact of mutation sets in receptor-binding domain of SARS-CoV-2 variants on the stability of RBD-ACE2 complex. SARS-CoV-2变异体受体结合域突变集对RBD-ACE2复合物稳定性的影响
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2023-03-01 DOI: 10.2217/fvl-2022-0152
Mykyta Peka, Viktor Balatsky

Aim: Bioinformatic analysis of mutation sets in receptor-binding domain (RBD) of currently and previously circulating SARS-CoV-2 variants of concern (VOCs) and interest (VOIs) to assess their ability to bind the ACE2 receptor. Methods: In silico sequence and structure-oriented approaches were used to evaluate the impact of single and multiple mutations. Results: Mutations detected in VOCs and VOIs led to the reduction of binding free energy of the RBD-ACE2 complex, forming additional chemical bonds with ACE2, and to an increase of RBD-ACE2 complex stability. Conclusion: Mutation sets characteristic of SARS-CoV-2 variants have complex effects on the ACE2 receptor-binding affinity associated with amino acid interactions at mutation sites, as well as on the acquisition of other viral adaptive advantages.

目的:通过生物信息学分析当前和以前流行的SARS-CoV-2关注变异体(VOCs)和感兴趣变异体(VOIs)的受体结合域(RBD)突变集,评估其结合ACE2受体的能力。方法:采用计算机序列法和结构定向法评价单突变和多突变的影响。结果:在VOCs和VOIs中检测到的突变导致RBD-ACE2复合物的结合自由能降低,与ACE2形成额外的化学键,RBD-ACE2复合物的稳定性增加。结论:SARS-CoV-2变异的突变集特征对突变位点氨基酸相互作用相关的ACE2受体结合亲和力以及其他病毒适应性优势的获得具有复杂的影响。
{"title":"The impact of mutation sets in receptor-binding domain of SARS-CoV-2 variants on the stability of RBD-ACE2 complex.","authors":"Mykyta Peka,&nbsp;Viktor Balatsky","doi":"10.2217/fvl-2022-0152","DOIUrl":"https://doi.org/10.2217/fvl-2022-0152","url":null,"abstract":"<p><p><b>Aim:</b> Bioinformatic analysis of mutation sets in receptor-binding domain (RBD) of currently and previously circulating SARS-CoV-2 variants of concern (VOCs) and interest (VOIs) to assess their ability to bind the ACE2 receptor. <b>Methods:</b> <i>In silico</i> sequence and structure-oriented approaches were used to evaluate the impact of single and multiple mutations. <b>Results:</b> Mutations detected in VOCs and VOIs led to the reduction of binding free energy of the RBD-ACE2 complex, forming additional chemical bonds with ACE2, and to an increase of RBD-ACE2 complex stability. <b>Conclusion:</b> Mutation sets characteristic of SARS-CoV-2 variants have complex effects on the ACE2 receptor-binding affinity associated with amino acid interactions at mutation sites, as well as on the acquisition of other viral adaptive advantages.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/97/65/fvl-2022-0152.PMC10089296.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9321830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Targeting ‘immunogenic hotspots’ in Dengue and Zika virus: an in silico approach to a common vaccine candidate 针对登革热和寨卡病毒的“免疫原性热点”:一种常见候选疫苗的计算机方法
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2023-02-24 DOI: 10.2217/fvl-2022-0104
Dhrubajyoti Mahata, Debangshu Mukherjee, Kheerthana Duraivelan, Vanshika Malviya, P. Parida, G. Mukherjee
Aim: Dengue and Zika viruses cause significant mortality globally. Considering high sequence similarity between the viral proteins, we designed common multi-epitope vaccine candidates against these pathogens. Methods: We identified multiple T and B cell epitope-rich conserved ‘immunogenic hotspots’ from highly antigenic and phylogenetically related viral proteins and used these to design the multi-epitope vaccine (MEV) candidates, ensuring high global population coverage. Results: Four MEV candidates containing conserved immunogenic hotspots from E and NS5 proteins with the highest structural integrity could favorably interact with TLR4-MD2 complex in molecular docking studies, indicating activation of TLR-mediated immune responses. MEVs also induced memory responses in silico, hallmarks of a good vaccine candidate. Conclusion: Conserved immunogenic hotspots can be utilized to design cross-protective MEV candidates.
目的:登革热和寨卡病毒在全球范围内造成重大死亡。考虑到病毒蛋白之间的高度序列相似性,我们设计了针对这些病原体的常见多表位候选疫苗。方法:我们从高度抗原和系统发育相关的病毒蛋白中鉴定了多个富含T和B细胞表位的保守“免疫原性热点”,并用这些来设计多表位候选疫苗(MEV),确保高全球人群覆盖率。结果:在分子对接研究中,四种含有E和NS5蛋白保守免疫原性热点的MEV候选物具有最高的结构完整性,可以与TLR4-MD2复合物有利地相互作用,表明TLR介导的免疫反应被激活。MEV还诱导了计算机的记忆反应,这是良好候选疫苗的标志。结论:保留的免疫原性热点可用于设计交叉保护性MEV候选物。
{"title":"Targeting ‘immunogenic hotspots’ in Dengue and Zika virus: an in silico approach to a common vaccine candidate","authors":"Dhrubajyoti Mahata, Debangshu Mukherjee, Kheerthana Duraivelan, Vanshika Malviya, P. Parida, G. Mukherjee","doi":"10.2217/fvl-2022-0104","DOIUrl":"https://doi.org/10.2217/fvl-2022-0104","url":null,"abstract":"Aim: Dengue and Zika viruses cause significant mortality globally. Considering high sequence similarity between the viral proteins, we designed common multi-epitope vaccine candidates against these pathogens. Methods: We identified multiple T and B cell epitope-rich conserved ‘immunogenic hotspots’ from highly antigenic and phylogenetically related viral proteins and used these to design the multi-epitope vaccine (MEV) candidates, ensuring high global population coverage. Results: Four MEV candidates containing conserved immunogenic hotspots from E and NS5 proteins with the highest structural integrity could favorably interact with TLR4-MD2 complex in molecular docking studies, indicating activation of TLR-mediated immune responses. MEVs also induced memory responses in silico, hallmarks of a good vaccine candidate. Conclusion: Conserved immunogenic hotspots can be utilized to design cross-protective MEV candidates.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41824120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Let’s make this go viral: welcome to your 18th dose of Future Virology 让我们让它像病毒一样传播开来:欢迎来到你的第18剂未来病毒学
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2023-02-03 DOI: 10.2217/fvl-2023-0002
Ellen Porter
{"title":"Let’s make this go viral: welcome to your 18th dose of Future Virology","authors":"Ellen Porter","doi":"10.2217/fvl-2023-0002","DOIUrl":"https://doi.org/10.2217/fvl-2023-0002","url":null,"abstract":"","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45954481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A twisting tale of misinformation: should ivermectin be approved as a treatment for COVID-19 disease? 一个扭曲的错误信息:伊维菌素应该被批准作为COVID-19疾病的治疗药物吗?
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2023-02-01 DOI: 10.2217/fvl-2023-0006
Arman Shafiee, Mohammad Mobin Teymouri Athar, Sayed-Hamidreza Mozhgani

This editorial examines what has caused the evidence around ivermectin to be so controversial, provides a brief analysis of recently published evidence, and highlights why it is important to learn lessons from ivermectin for future re-purposed drugs.

这篇社论审查了导致围绕伊维菌素的证据如此有争议的原因,对最近发表的证据进行了简要分析,并强调了为什么从伊维菌素中吸取教训对未来重新利用药物很重要。
{"title":"A twisting tale of misinformation: should ivermectin be approved as a treatment for COVID-19 disease?","authors":"Arman Shafiee,&nbsp;Mohammad Mobin Teymouri Athar,&nbsp;Sayed-Hamidreza Mozhgani","doi":"10.2217/fvl-2023-0006","DOIUrl":"https://doi.org/10.2217/fvl-2023-0006","url":null,"abstract":"<p><p>This editorial examines what has caused the evidence around ivermectin to be so controversial, provides a brief analysis of recently published evidence, and highlights why it is important to learn lessons from ivermectin for future re-purposed drugs.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9465281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Two sides of the same coin: the N-terminal and the receptor binding domains of SARS-CoV-2 Spike. 同一枚硬币的两面:SARS-CoV-2 Spike的n端和受体结合域。
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2023-02-01 DOI: 10.2217/fvl-2022-0181
Massimo Ciccozzi, Stefano Pascarella

The SARS-CoV-2 Spike receptor binding domain and N-terminal domain interact with each other in an intricate mechanism. Mutations modulate the interplay between the Spike and host molecules. This editorial comments on the intricacies of SARS-CoV-2 Spike interactions.

SARS-CoV-2刺突受体结合域和n端结构域以复杂的机制相互作用。突变调节了刺突和宿主分子之间的相互作用。这篇社论评论了SARS-CoV-2刺突相互作用的复杂性。
{"title":"Two sides of the same coin: the N-terminal and the receptor binding domains of SARS-CoV-2 Spike.","authors":"Massimo Ciccozzi,&nbsp;Stefano Pascarella","doi":"10.2217/fvl-2022-0181","DOIUrl":"https://doi.org/10.2217/fvl-2022-0181","url":null,"abstract":"<p><p>The SARS-CoV-2 Spike receptor binding domain and N-terminal domain interact with each other in an intricate mechanism. Mutations modulate the interplay between the Spike and host molecules. This editorial comments on the intricacies of SARS-CoV-2 Spike interactions.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9438255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Natural killer cells in COVID-19: from infection, to vaccination and therapy. COVID-19中的自然杀伤细胞:从感染到疫苗接种和治疗。
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2023-02-01 DOI: 10.2217/fvl-2022-0040
Alireza Zafarani, Mohammad Hossein Razizadeh, Salar Pashangzadeh, Mohammad Reza Amirzargar, Mahsa Taghavi-Farahabadi, Mohammad Mahmoudi
Natural killer (NK) cells are among the most important innate immunity members, which are the first cells that fight against infected cells. The function of these cells is impaired in patients with COVID-19 and they are not able to prevent the spread of the disease or destroy the infected cells. Few studies have evaluated the effects of COVID-19 vaccines on NK cells, though it has been demonstrated that DNA vaccines and BNT162b2 can affect NK cell response. In the present paper, the effects of SARS-CoV-2 on the NK cells during infection, the effect of vaccination on NK cells, and the NK cell-based therapies were reviewed.
自然杀伤细胞(NK)是最重要的先天免疫成员之一,是第一个对抗感染细胞的细胞。在COVID-19患者中,这些细胞的功能受损,它们无法阻止疾病的传播或破坏受感染的细胞。很少有研究评估COVID-19疫苗对NK细胞的影响,尽管已经证明DNA疫苗和BNT162b2可以影响NK细胞的反应。本文就SARS-CoV-2在感染过程中对NK细胞的影响、疫苗接种对NK细胞的影响以及NK细胞为基础的治疗方法进行综述。
{"title":"Natural killer cells in COVID-19: from infection, to vaccination and therapy.","authors":"Alireza Zafarani,&nbsp;Mohammad Hossein Razizadeh,&nbsp;Salar Pashangzadeh,&nbsp;Mohammad Reza Amirzargar,&nbsp;Mahsa Taghavi-Farahabadi,&nbsp;Mohammad Mahmoudi","doi":"10.2217/fvl-2022-0040","DOIUrl":"https://doi.org/10.2217/fvl-2022-0040","url":null,"abstract":"Natural killer (NK) cells are among the most important innate immunity members, which are the first cells that fight against infected cells. The function of these cells is impaired in patients with COVID-19 and they are not able to prevent the spread of the disease or destroy the infected cells. Few studies have evaluated the effects of COVID-19 vaccines on NK cells, though it has been demonstrated that DNA vaccines and BNT162b2 can affect NK cell response. In the present paper, the effects of SARS-CoV-2 on the NK cells during infection, the effect of vaccination on NK cells, and the NK cell-based therapies were reviewed.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013930/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9186944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Plain language summary of Pfizer-BioNTech BNT162b2 vaccine protection against COVID-19 and its safety in participants 12- to 15-years-old 辉瑞- biontech BNT162b2疫苗对COVID-19的保护作用及其在12- 15岁参与者中的安全性
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2023-01-16 DOI: 10.2217/fvl-2022-0169
R. Frenck, N. Klein, N. Kitchin, A. Gurtman, J. Absalon, S. Lockhart, John L. Perez, E. Walter, S. Senders, R. Bailey, K. Swanson, Hua Ma, Xia Xu, K. Koury, W. Kalina, D. Cooper, Timothy W Jennings, Donald M Brandon, Stephen J. Thomas, Ö. Türeci, D. Tresnan, S. Mather, P. Dormitzer, U. Şahin, K. Jansen, W. Gruber
This is a summary of an article about part of a clinical study for the BNT162b2 COVID-19 vaccine, also called the Pfizer-BioNTech vaccine. The article was published in the New England Journal of Medicine in May 2021. This summary describes how the vaccine worked in participants 12- to 15-years old. The part of the study described in the article is ongoing and expected to finish March 2023. This means that the final results may be different from the results included in this summary. The part of the study described in this summary included participants 12- to 15-years old who had no serious health issues. The BNT162b2 vaccine had already been studied in participants 16 years of age or older. In this part of the study, the researchers wanted to find out: How effective and safe the vaccine was in participants 12- to 15-years old. What the immune response to the vaccine and the vaccine safety were like in 12- to 15-year-olds compared with 16- to 25-year-olds. How well the vaccine prevented SARS-CoV-2 infections in participants who received the vaccine compared to those who did not. This is also called efficacy of the BNT162b2 vaccine Half of the participants in this study received 2 injections of the BNT162b2 vaccine and half received 2 injections of a placebo in a muscle of the upper arm. The placebo looked like the BNT162b2 vaccine but did not have any active vaccine in it. BNT162b2 had a favorable safety profile. The most common reactions were pain at the injection site, fatigue, and headache. None of the participants had serious reactions to the vaccine. The 12- to 15-year-old participants' immune system responses to the BNT162b2 vaccine were as good as or stronger than the 16- to 25-year-old participants' immune responses. The participants who received the BNT162b2 vaccine were less likely to get COVID-19 compared with the participants who got the placebo. Clinical Trial Registration: NCT04368728 ( ClinicalTrials.gov )
这是一篇关于BNT162b2新冠肺炎疫苗(也称为Pfizer-BioNTech疫苗)临床研究部分内容的文章摘要。这篇文章于2021年5月发表在《新英格兰医学杂志》上。该摘要描述了疫苗如何在12至15岁的参与者中发挥作用。文章中描述的这部分研究正在进行中,预计将于2023年3月结束。这意味着最终结果可能与本摘要中包含的结果不同。本摘要中描述的研究部分包括12至15岁的参与者,他们没有严重的健康问题。BNT162b2疫苗已经在16岁或以上的参与者中进行了研究。在这部分研究中,研究人员想弄清楚:疫苗在12至15岁的参与者中的有效性和安全性。与16至25岁的人相比,12至15岁的人对疫苗的免疫反应和疫苗的安全性是什么样的。与未接种疫苗的参与者相比,疫苗预防严重急性呼吸系统综合征冠状病毒2型感染的效果如何。这也被称为BNT162b2疫苗的疗效本研究的一半参与者在上臂肌肉中注射了2针BNT162b2疫苗,一半参与者注射了2剂安慰剂。安慰剂看起来像BNT162b2疫苗,但其中没有任何活性疫苗。BNT162b2具有良好的安全性。最常见的反应是注射部位疼痛、疲劳和头痛。没有一名参与者对疫苗有严重反应。12至15岁参与者对BNT162b2疫苗的免疫系统反应与16至25岁参与者的免疫反应一样好或更强。与接种安慰剂的参与者相比,接种BNT162b2疫苗的参与者感染新冠肺炎的可能性较小。临床试验注册:NCT04368728(ClinicalTrials.gov)
{"title":"Plain language summary of Pfizer-BioNTech BNT162b2 vaccine protection against COVID-19 and its safety in participants 12- to 15-years-old","authors":"R. Frenck, N. Klein, N. Kitchin, A. Gurtman, J. Absalon, S. Lockhart, John L. Perez, E. Walter, S. Senders, R. Bailey, K. Swanson, Hua Ma, Xia Xu, K. Koury, W. Kalina, D. Cooper, Timothy W Jennings, Donald M Brandon, Stephen J. Thomas, Ö. Türeci, D. Tresnan, S. Mather, P. Dormitzer, U. Şahin, K. Jansen, W. Gruber","doi":"10.2217/fvl-2022-0169","DOIUrl":"https://doi.org/10.2217/fvl-2022-0169","url":null,"abstract":"This is a summary of an article about part of a clinical study for the BNT162b2 COVID-19 vaccine, also called the Pfizer-BioNTech vaccine. The article was published in the New England Journal of Medicine in May 2021. This summary describes how the vaccine worked in participants 12- to 15-years old. The part of the study described in the article is ongoing and expected to finish March 2023. This means that the final results may be different from the results included in this summary. The part of the study described in this summary included participants 12- to 15-years old who had no serious health issues. The BNT162b2 vaccine had already been studied in participants 16 years of age or older. In this part of the study, the researchers wanted to find out: How effective and safe the vaccine was in participants 12- to 15-years old. What the immune response to the vaccine and the vaccine safety were like in 12- to 15-year-olds compared with 16- to 25-year-olds. How well the vaccine prevented SARS-CoV-2 infections in participants who received the vaccine compared to those who did not. This is also called efficacy of the BNT162b2 vaccine Half of the participants in this study received 2 injections of the BNT162b2 vaccine and half received 2 injections of a placebo in a muscle of the upper arm. The placebo looked like the BNT162b2 vaccine but did not have any active vaccine in it. BNT162b2 had a favorable safety profile. The most common reactions were pain at the injection site, fatigue, and headache. None of the participants had serious reactions to the vaccine. The 12- to 15-year-old participants' immune system responses to the BNT162b2 vaccine were as good as or stronger than the 16- to 25-year-old participants' immune responses. The participants who received the BNT162b2 vaccine were less likely to get COVID-19 compared with the participants who got the placebo. Clinical Trial Registration: NCT04368728 ( ClinicalTrials.gov )","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45278093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Future Virology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1